Biotechnology: Class 12 — Chapter 9: Stem Cell Culture and Organ Culture

• 1998: Derivation of the first human embryonic stem cell (hESC) line.
• 2004: Discovery of germ cell potential; human ESCs shown to differentiate into ecto-, endo-, mesoderm, and germ cell lineages.
• 2006: Development of xeno-free culture conditions to completely eliminate animal products from hESC culture.
• 2007: Generation of human induced pluripotent stem cells (hiPSCs).
• 2009: Initiation of the first clinical trials using hiPSCs.
• 2010: First report of naive state hESCs.
• 2012: Nobel Prize awarded to Dr. Shinya Yamanaka and Sir John Gurdon for discovering that mature cells can be reprogrammed to become pluripotent.
• 2013: First derivation of hESCs by therapeutic cloning via Somatic Cell Nuclear Transfer (SCNT).
• 2014: Initiation of the first clinical trials with hESCs.
• 2015: Application of CRISPR/Cas9 technology for gene editing in hESCs, and generation of hESC-derived organoids for modeling fetal organ morphogenesis.
• 2017: Continuation and expansion of clinical trials with hESCs.

Stem cells are categorized into three major groups based on their biological origin:

• Hematopoietic Stem Cells (HSCs): Adult stem cells in the bone marrow that give rise to all blood cell types (RBCs, monocytes, neutrophils, acidophils, basophils, lymphocytes, platelets).
• Mesenchymal Stem Cells (MSCs): Highly proliferative, genetically stable cells isolated from bone marrow, adipose tissue, and umbilical cord; capable of repairing skeletal tissues (cartilage, bone, fat) without inducing allo-rejection.

Stem cells are classified based on their differentiation potential:

• Plasticity: The ability of tissue-specific adult stem cells to adopt cell fates distinct from their tissue of origin.
• Trans-determination: A pathway where a stem cell programmed for a specific lineage switches to another stem cell type, redirecting its potential.
• Trans-differentiation: A process where a fully differentiated cell directly achieves the phenotype of another differentiated cell type.
• Dedifferentiation: A process where adult stem cells revert back to more primitive master cells, which can then differentiate into other cell types (common in lower vertebrates, rare in mammals).
• Pleiotropy: Plasticity between two cells originated from the same germ layer explained by clonal-level impurity.
• Fusion: An alternative mechanism proposed for adult stem cell plasticity via cell-to-cell fusion.

• Neurological Diseases: Clinical trials are investigating bone marrow stem cells and hiPSCs for treating Amyotrophic Lateral Sclerosis (ALS), spinal cord injuries (regenerating nerve fibers), and eye diseases (transplanting retinal pigment epithelial cells).
• Wound Healing & Skin Replacement: Culturing keratinocyte stem cells plucked from hair follicles to develop autologous skin grafts for burn wounds with minimal rejection risk.
• Cardiovascular Diseases: Investigating therapies to re-establish the function of damaged heart tissue and blood vessels following ischemia and congestive heart failure.
• Auto-immune Disorders: Exploring hematopoietic stem cell-derived therapies for Type 1 Diabetes (replacing degraded pancreatic beta cells), Multiple Sclerosis (regenerating myelin sheaths), and Rheumatoid Arthritis (differentiating stem cells into chondrocytes to repair joint cartilage).
• Pharmaceutical Drug Screening: Utilizing human ESC-derived cardiomyocytes and neuronal cells as in vitro models to test drug efficacy, mode of action, and toxicity, reducing reliance on animal models.

The protocol for maintaining Mouse Embryonic Fibroblasts (MEFs) in culture involves the following sequential steps:

1. Digest MEFs with 0.25% trypsin/EDTA to obtain single cells.
2. Transfer MEFs to 10cm dishes and adjust density to $8 \times 10^4$ to $1.1 \times 10^5$ cells/cm².
3. Incubate for 2.0–3.0 hours at 37°C.
4. Add Macromolecular Crowding (MMC) (10 mg/mL) to medium and incubate for 0.5–3.5 hours at 37°C.
5. Rapidly aspirate and discard the medium containing MMC and non-adherent cells.
6. Wash with Phosphate Buffer Saline (PBS) 5 times.
7. Digest adherent cells with 0.25% trypsin/EDTA.
8. Transfer cells into a tube and centrifuge.
9. Cryopreserve for later use.

• Immunological Rejection: Recipient immune systems often reject foreign stem cell transplants, requiring immunosuppressive therapies that increase infection risks.
• Tumorigenicity: Pluripotent stem cells (like ESCs) that divide indefinitely carry a high risk of inducing tumor or teratoma growth in vivo.
• Safety & Contamination: Stem cell cultures are highly vulnerable to microbial infections, which can transmit infectious diseases to recipients.

• Structural Integrity: Unlike isolated cell cultures, organ cultures preserve cell-to-cell communication, spatial association, and histological architecture. However, the lack of a vascular system restricts the tissue size due to diffusion limitations.
• Nutrient and Gas Exchange: Devoid of blood vessels, gas and nutrient exchange occurs solely via peripheral diffusion. If the tissue mass is too large, central necrosis occurs. Cultures are maintained at a gas-liquid interface to optimize exchange without causing tissue flattening from surface tension.

Most organ cultures do not grow in size; instead, cell proliferation is restricted to the outer layers due to physical and structural constraints. Soluble growth factors are supplied to direct differentiation rather than cell division.

Spratt (1950s) explained the effect of metabolic inhibitors on the developing embryo in vitro.

---

Engineering Methodology & Mechanism: To culture the embryo, a suitable medium is prepared and poured onto a watchglass, placed on a moist absorbent cotton wool pad in a petridish. The chick embryo is explanted, vitelline membrane removed, and incubated at 37.5°C to observe blastoderm development under controlled metabolic inhibition.

• Organoids: Self-organized 3D tissue cultures derived from stem cells using a combination of cells, growth factors, and extracellular matrices (e.g., artificial liver implanted into rats).

• Applications: Serves as substitutes for transplantable organs; allows direct in vitro study of tissue behavior, hormone responses, and biochemical functions.
• Limitations: Highly dependent on histological techniques; low reproducibility and high variation; cannot proliferate indefinitely, requiring a fresh donor organ for every experiment; technically challenging and expensive.
• Future Prospects: Adapting 2D assay protocols to 3D structures, including multicellular spheroids, scaffold hydrogels, organs-on-chips, microfluidics, magnetic levitation, and 3D bioprinting.